Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Free Cash Flow (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Free Cash Flow for 11 consecutive years, with -$18.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 3477.37% to -$18.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$79.4 million, a 223.78% decrease, with the full-year FY2025 number at -$79.4 million, down 223.78% from a year prior.
  • Free Cash Flow was -$18.2 million for Q4 2025 at Cartesian Therapeutics, up from -$19.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $8.2 million in Q3 2024 to a low of -$32.5 million in Q4 2021.
  • A 5-year average of -$12.4 million and a median of -$12.1 million in 2021 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 188.79% in 2024, then crashed 3477.37% in 2025.
  • Cartesian Therapeutics' Free Cash Flow stood at -$32.5 million in 2021, then surged by 63.97% to -$11.7 million in 2022, then tumbled by 99.22% to -$23.3 million in 2023, then surged by 102.31% to $539000.0 in 2024, then plummeted by 3477.37% to -$18.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Free Cash Flow are -$18.2 million (Q4 2025), -$19.9 million (Q3 2025), and -$17.1 million (Q2 2025).